Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)

Rosenthal, Éric; Poirée, Marilyne; Pradier, Christian; Perronne, Christian; Salmon‐Céron, Dominique; Geffray, L.; Myers, Robert P.; Morlat, Philippe; Pialoux, Gilles; Pol, Stanislas; Cacoub, Patrice

doi:10.1097/00002030-200308150-00009

Cited by 241 publications

(197 citation statements)

References 21 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…Consequently, cirrhosis caused by HCV has become a major cause of death in some areas. 9,10 These facts have led some experts to consider liver transplantation as a suitable therapeutic tool in coinfected patients with HCV-related ESLD. 11,12 The results recently reported in a case series dealing with the outcome of HIVinfected liver transplant recipients suggest that survival does not differ from that of HIV-negative patients.…”

Section: T Is Well Known That Human Immunodeficiency Virusmentioning

confidence: 99%

HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis†

et al. 2005

View full text Add to dashboard Cite

Section: T Is Well Known That Human Immunodeficiency Virusmentioning

confidence: 99%

HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis†

et al. 2005

View full text Add to dashboard Cite

“…11 Once established, HIV-1 infection seems to increase the persistence of the hepatitis C virus, the level of HCV RNA and progression of HCV-related disease. [12][13][14][15][16] There are conflicting reports concerning whether HCV infection alters the course of HIV. 17 Some studies before the advent of highly active anti-retroviral therapy (HAART) suggested that survival and progression to AIDS were the same in patients with HCV/HIV co-infection as in those with HIV alone 18,19 whereas others suggested an adverse effect.…”

mentioning

confidence: 99%

Hepatitis C infection is not associated with systemic HIV‐associated non‐hodgkin's lymphoma: A cohort study

Waters¹,

Stebbing²,

Mandalia³

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Immunosuppression induced by the human immunodeficiency virus (HIV) increases the risk of developing non-Hodgkin's lymphoma (NHL). As the hepatitis C virus (HCV) has been implicated in the development of B cell lymphomas, we compared the incidence of systemic NHL during HIV infection compared to HIV and HCV co-infection. Of 5,832 individuals studied during the era of highly active anti-retroviral therapy (HAART), 102 patients were diagnosed with systemic NHL. The incidence of systemic NHL was 6.9 of 10 4 patient years during HIV infection compared to 7.1 of 10 4 patient years during HIV alone (p ¼ 0.9). In this immunocompromised patient population, there was no association between HCV infection and an increased risk of lymphoma. ' 2005 Wiley-Liss, Inc.Key words: hepatitis C; HIV; non-Hodgkin's lymphomaThe use of HAART has resulted in marked declines in HIVrelated morbidity and mortality, by mainly reducing the incidence of opportunistic infections 1 High grade B-cell non-Hodgkin's lymphoma (NHL) is an AIDS defining illness, having first been described in association with HIV in the early 1980s. 2 NHL occurs at a greatly increased frequency in HIV-infected populations and despite a reduction in its incidence during the HAART era, it remains the second commonest AIDS defining malignancy after Kaposi's sarcoma. [3][4][5][6][7] Many of the 200 million individuals infected with HCV and the 50 million individuals infected with HIV are co-infected with both viruses. [8][9][10] As well as shared routes of transmission, there are many interactions between these small RNA viruses in which infection is often characterised by parenteral transmission followed by a seroconversion illness and then a long latent period lasting many years. 11 Once established, HIV-1 infection seems to increase the persistence of the hepatitis C virus, the level of HCV RNA and progression of HCV-related disease. [12][13][14][15][16] There are conflicting reports concerning whether HCV infection alters the course of HIV. 17 Some studies before the advent of highly active anti-retroviral therapy (HAART) suggested that survival and progression to AIDS were the same in patients with HCV/HIV co-infection as in those with HIV alone 18,19 whereas others suggested an adverse effect. 13,20 In the pre-HAART era, HCV infection was deemed an irrelevance as it was HIV that affected morbidity and mortality. With the increased life expectancy of individuals with HIV, however, HCV has emerged as a problem that adversely affects survival of individuals with HIV. 8,16,21 HCV is a well-established risk factor in the etiology of hepatocellular carcinomas and of mixed cryoglobulinemia Type II, a condition that can evolve to malignant lymphoma in 8-10% of affected cases. 22 In the non-HIV setting, data from case-case comparisons and case-control studies indicate several-fold higher prevalence of HCV infection (as indicated by the presence of antibodies or HCV RNA) among B cell lymphoma patients compared to control populations. 23 Attempts have been made to evaluate an...

show abstract

“…Le carcinome hépatocellulaire ou cancer primitif du foie, est diagnostiqué à un âge plus jeune, et à un stade plus avancé chez les patients co-infectés VIH/VHB que dans la population mono-infectée, avec pour conséquence une survie plus courte [11]. En France, l'incidence annuelle du carcinome hépatocellulaire est 5 fois plus élevée dans la population co-infectée VIH/VHC que dans la population mono-infectée VHC [8]. …”

Section: Jean-charles Duclos-vallée Elina Teicher Daniel Vittecoq unclassified

La transplantation hépatique chez les patients co-infectés VIH/VHC et VIH/VHB

et al. 2007

View full text Add to dashboard Cite

Les infections par le virus de l'hépatite C (VHC) et le virus de l'immunodéficience humaine (VIH) sont des problè-mes de santé publique majeurs. Plus de 40 millions de personnes sont infectés par le VIH dans le monde, et 2 % à 3 % de la population sont infectés par le virus de l'hépatite C soit environ 175 millions de personnes. Dix millions d'individus sont co-infectés par le VIH et le VHC. La transmission de l'infection par le VHC, comme celle du VIH, s'effectue majoritairement par voie parentérale. Ainsi la co-infection VIH/VHC est volontiers fréquente dans la population toxicomane et celle des hémophiles. Une infection par le virus de l'hépatite C est présente chez 70 % à 90 % de la population hémophile et 60 % à 80 % de la population toxicomane.

show abstract

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)

Abstract: In the post-HAART era, ESLD due to HCV is a growing cause of mortality in HIV-infected patients. Increased longevity attributable to HAART, and a higher prevalence of alcohol consumption, are probably involved in this trend.

Cited by 241 publications

References 21 publications

HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis†

HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis†

Hepatitis C infection is not associated with systemic HIV‐associated non‐hodgkin's lymphoma: A cohort study

La transplantation hépatique chez les patients co-infectés VIH/VHC et VIH/VHB

Contact Info

Product

Resources

About